Enasidenib

Idhifa

Near Add Your Location

Accepting patients

Azacitidine and Enasidenib for IDH-2 Mutations

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Learn more
  • IDH2 Inhibitor
  • Phase 2

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Learn more
  • Genetic Sequencing
  • Phase 2